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Supplementary Table S1: Reactions and rate constants used in the simulations 
for Fig. 1. 
Rxn Model Expressions k1 k-1 kcat References 
1 Xa + VII → Xa + VIIa 1.3·107 M-1s-1   (20) 
2 IIa + VII → IIa + VIIa 2.3·104 M-1s-1   (20) 
3 II + Xa → IIa + Xa 7.5·103 M-1s-1   (20) 
4 IIa + VIII → IIa + VIIIa 2.0·107 M-1s-1   (20) 
5 VIIIa + IXa ↔ IXaVIIa 1.0·107 M-1s-1 5.0·10-3 s-1  (20) 
6 IXaVIIa + X ↔ IXaVIIaX → IXaVIIa + 
Xa 
1.0·108 M-1s-1 1.0·10-3 s-1 8.2 s-1 (20) 
7 VIIIa ↔ VIIIa1L + VIIIa2 6.0·10-3 s-1 2.2·104 M-1s-1  (20) 
8 IXaVIIIaX → VIIIa1L + VIIIa2 + X + 
IXa 
1.0·10-3 s-1   (20) 
9 IXaVIIIa → VIIIa1L + VIIIa2 + IXa 1.0·10-3 s-1   (20) 
10 IIa + V → IIa + Va 2.0·107 M-1s-1   (20) 
11 Xa+ Va ↔ XaVa 7.5·103 M-1s-1 0.2 s-1  (20) 
12 XaVa + II ↔ XaVaII → XaVa + mIIa 1.0·108 M-1s-1 103 s-1 63.5 s-1 (20) 
13 XaVa + mIIa → XaVa + IIa 1.5·107 M-1s-1   (20) 
14 Xa + TFPI ↔ XaTFPI 9.0·105 M-1s-1 3.6·10-4 s-1  (20) 
15 Xa + ATIII → XaATIII 1.5·10-3 M-1s-1   (20) 
16 mIIa + ATIII → mIIaATIII 7.1·103 M-1s-1   (20) 
17 IXa + ATIII → IXaATIII 4.9·102 M-1s-1   (20) 
18 IIa + ATIII → IIaATIII 7.1·103 M-1s-1   (20) 
19 XIIa + XII ↔ XIIaXII → XIIa + XIIa 1.0·108 M-1s-1 750 s-1 3.3·10-2 s-1 (20) 
20 XIIa + PK ↔ XIIaPK → XIIa + K 1.0·108 M-1s-1 3.6·103 s-1 40 s-1 (20) 
21 XII + K ↔ XIIK → XIIa + K 1.0·108 M-1s-1 45.3 s-1 5.7 s-1 (20) 
22 PK + K → K + K 2.7·104 M-1s-1   (20) 
23 K → KInhibited 1.1·10-2 s-1   (20) 
24 XIIa + C1inh → XIIaC1inh 3.6·103 M-1s-1   (20) 
25 XIIa + ATIII → XIIaATIII 21.6 M-1s-1   (20) 
26 XI + IIa ↔ XIIIa → XIa + IIa 1.0·108 M-1s-1 5.0 s-1 1.3·10-4 s-1 (20) 
27 XIIa + XI ↔ XIIaXI → XIIa + XIa 1.0·108 M-1s-1 200 s-1 5.7·10-4 s-1 (20) 
28 XIa + XI → XIa + XIa 3.19·106 M-1s-1   (20) 
29 XIa + ATIII → XIaATIII 3.2·102 M-1s-1   (20) 
30 XIa + C1inh → XIaC1inh 1.8·103 M-1s-1   (20) 
31 XIa + a1AT → XIaa1AT 1.0·102 M-1s-1   (20) 
32 XIa + a2AP → XIaa2AP 4.3·103 M-1s-1   (20) 
33 XIa + IX ↔ XIaIX → XIa + IXa 1.0·108 M-1s-1 41 s-1 7.7 s-1 (20) 
34 IXa + X ↔ IXaX → IXa + Xa 1.0·108 M-1s-1 0.64 s-1 7.0·10-4 s-1 (20) 
35 Xa + VIII ↔ XaVIII → Xa + VIIIa 1.0·108 M-1s-1 2.1 s-1 0.023 s-1 (20) 
36 VIIa + IX ↔ VIIaIX → VIIa + IXa 1.0·108 M-1s-1 0.9 s-1 3.6·10-5 s-1 (20) 
37 VIIa + X ↔ VIIaX → VIIa + Xa 1.0·108 M-1s-1 210 s-1 1.6·10-6 s-1 (20) 
38* polyP + TFPI ↔ polyPTFPI 4.0·105 M-1s-1 1.0·10-2 s-1  (4),(5) 
39* V + Xa + polyP → Va + Xa + polyP 8.0·1012 M-2s-1   (20),(4) 
40* XI + IIa + polyP → XIa + IIa + polyP 8.8·109 M-2s-1   (5) 
*Reactions 38-40 are bulk reactions for dispersed polyP simulations (D-polyP) and 
surface reactions for the surface-immobilized polyP simulations (SI-polyP). 
Reaction 38: polyP abrogates TFPI function (4). 
For polyP binding to TFPI, similar rate constants were used as when polyP binds and 
releases from other plasma proteins.  The association rate constant for the polyP 
reaction with  IIa, XI, and XIa ranges from 1.64·106 M-1s-1 to 5.12·106 M-1s-1 (5); thus, 
1.0·106 M-1s-1 was chosen for 𝑘1,38.  The disassociation rate constant for the polyP 
reaction with  IIa, XI, and XIa ranges from 1.05·10-2 s-1 to 7.71·10-2 s-1 (5); thus, 
1.0·10-2 s-1 was chosen for 𝑘−1,38. 
Reaction 39: polyP accelerates V activation by Xa (4). 
The activation of V to Va by IIa occurs with a rate constant (𝑘1,10) of 2.0·10
7 M-1s-1 
(see Reaction 10 in Table S1) (20).  The reaction is 𝑉 + 𝐼𝐼𝑎 → 𝑉𝑎 + 𝐼𝐼𝑎 and the rate 
law is: 
𝑑[𝑉𝑎]
𝑑𝑡
= 𝑘1,10[𝑉][𝐼𝐼𝑎] 
PolyP accelerates the activation of V by Xa; we assume this occurs with a similar rate 
as that of V activation by IIa.  The reaction would be 𝑉 + 𝑋𝑎 + 𝑝𝑜𝑙𝑦𝑃 → 𝑉𝑎 + 𝑋𝑎 +
𝑝𝑜𝑙𝑦𝑃 and the rate law would be:  
𝑑[𝑉𝑎]
𝑑𝑡
= 𝑘1,39[𝑉][𝑋𝑎][𝑝𝑜𝑙𝑦𝑃] 
To approximate the rate constant, we assume that 𝑘1,10 ~ 𝑘1,39[𝑝𝑜𝑙𝑦𝑃].  With a typical 
[𝑝𝑜𝑙𝑦𝑃]~1𝜇𝑀, this means that 𝑘1,39 ~ 2.0 ∙ 10
13𝑀−2𝑠−1. 
Reaction 40: polyP enhances XI activation by thrombin (5). 
A simple reaction for polyP enhancing XI activation by thrombin would be 𝑋𝐼 + 𝐼𝐼𝑎 +
𝑝𝑜𝑙𝑦𝑃 → 𝑋𝐼𝑎 + 𝐼𝐼𝑎 + 𝑝𝑜𝑙𝑦𝑃.  The rate law would be: 
𝑑[𝑋𝐼𝑎]
𝑑𝑡
= 𝑘1,39[𝑋𝐼][𝐼𝐼𝑎][𝑝𝑜𝑙𝑦𝑃] 
For an estimate of the reaction rate constant for polyP enhancing XI activation, Fig. 
1a from Reference shows a XI activation rate of ~1 nM/min when ~5 μM polyP is 
present.  The concentrations used in this figure were [𝑋𝐼] = 30 𝑛𝑀 and [𝐼𝐼𝑎] = 5 𝑛𝑀.  
Therefore, 
𝑘1,40 ~ 
1
𝑛𝑀
𝑚𝑖𝑛
(30 𝑛𝑀)(5 𝑛𝑀)(5 𝜇𝑀)
~2.2 · 1010
1
𝑀2𝑠1
 
For all polyP reactions, elementary mass action kinetics was assumed.  Also, the 
experiments that the rate constants were based were in bulk solutions, whereas the 
experiments performed for this paper were in microfluidic devices.  To account for 
this, a factor 𝜂 was multiplied to each polyP forward rate constant (𝑘1,38, 𝑘1,39, 𝑘1,40) 
and simulations were run to match the clotting time in the microfluidic device.  𝜂 
was found to be ~0.4, so the final rate constants used are as appears in Table S1 
(𝑘1,38 = 4.0·10
5 M-1s-1, 𝑘1,39 = 8.0·10
12 M-2s-1, 𝑘1,40 = 8.8·10
9 M-2s-1). 
 
Supplementary Table S2: Chemical species and their initial concentrations used 
in the simulations for Fig. 1. All initial concentrations were taken from Reference 
(20). 
Species Initial Concentration (M) 
VII 1·10-8 
VIIa 1·10-10 
Xa 0 
IIa 0 
X 1.6·10-7 
IX 9·10-8 
II 1.4·10-6 
VIII 7·10-10 
VIIIa 0 
IXaVIIIa 0 
IXaVIIIaX 0 
VIIIa1L 0 
VIIIa2 0 
V 2·10-8 
Va 0 
XaVa 0 
XaVaII 0 
mIIa 0 
TFPI 2.5·10-9 
XaTFPI 0 
ATIII 3.4·10-6 
XaATIII 0 
mIIaATIII 0 
IXaATIII 0 
IIaATIII 0 
XII 3.4·10-7 
XIIa 0 
XIIaXII 0 
PK0 4.5·10-7 
XIIaPK 0 
XIIK 0 
K 0 
C1inh 2.5·10-6 
XIIaC1inh 0 
XIIaATIII 0 
XI 3.1·10-8 
XIIIa 0 
XIa 0 
XIIaXI 0 
XIaATIII 0 
XIaC1inh 0 
a1AT 4.5·10-5 
a2AP 1·10-6 
XIaa1AT 0 
XIaa2AP 0 
XIaIX 0 
IXaX 0 
XaVIII 0 
VIIaIX 0 
VIIaX 0 
KInhibited 0 
polyP ** 
**For the polyP concentration, the same number of polyP molecules (7.5·10-9 moles) 
was either i) localized to the surface of the cylinder, or ii) dispersed throughout the 
volume of the cylinder.  This corresponds to a surface polyP concentration of 3·10-5 
mol/m2 in the SI-polyP simulations and a dispersed polyP concentration of 3·10-2 
mol/m3 in the D-polyP simulations. 
 
 
 
 
Supplementary Table S3: Shear rates used in the simulations for Fig. 1b and the 
resulting thrombin concentration for dispersed and localized polyP.  
Shear 
rate 
[thrombin]SI-polyP 
(mol/m3) 
[thrombin]D-polyP 
(mol/m3) 
[thrombin]SI-polyP / 
[thrombin]D-polyP 
1 1.83·10-5 2.34·10-8 782.1 
4 1.72·10-9 1.65·10-11 104.2 
12 4.70·10-12 1.93·10-13 24.4 
24 8.40·10-14 2.98·10-14 2.8 
60 1.87·10-15 1.95·10-15 1.0 
120 2.40·10-16 2.36·10-16 1.0 
 
 
 
 
 Supplementary Figure S1. Size distribution of NP-polyP160. Representative DLS 
data demonstrating  NP-polyP160 consisting of particles with an average 
hydrodynamic diameter of 250 ± 65 nm. 
 
 
Supplementary Figure S2. polyP facilitates clotting through activation of Factor 
XII. Clotting times of normal plasma and FXII-deficient plasma at zero-shear with SI-
polyP70 or without (biotinylated-PC alone). Data indicate mean ± SEM, n=3.   
  
 
 
Supplementary Figure S3. DLS size distribution of soluble D-polyP160 and NP-
polyP160 in buffer and plasma. (A) Normal citrated plasma without polyP, which 
contains background intensity from components normally in plasma. (B-C) 
Aggregated and soluble polyP160 respectively in HEPES buffered saline. (D) Soluble 
polyP160 added to citrated plasma. (E) Preformed NP-polyP160 added to citrated 
plasma. (F) Soluble polyP160 was added to citrated plasma and recalcified; the graph 
of panel F resembles panel D (D-polyP) rather than panel E (NP-polyP).  
 
 
Supplementary Figure S4. PC channel coverage and stability. (A) Representative 
time lapse images of a channel (white dashed lines) coated with PC/Texas Red DHPE 
(red) with citrated normal plasma flowing through it. (B) Fluorescence intensities in 
different regions of each shear chamber. Data indicate mean ± SEM. 
 
 Supplementary Figure S5. Fluorescent beads do not influence clotting. Normal 
recalcified plasma (with or without beads) was flowed into the device and clotting 
times at zero-shear were measured by bright-field microscopy. Data indicate mean ± 
SEM, n=3.  
 
 
